LIRAGLUTIDE
As an adjunct to diet and exercise in management of type 2 diabetes mellitus.
1.2-1.8 mg once daily subcutaneously, irrespective of meals. Maximum dialy dose : 1.8 mg.
In patients with a personal or family history of medullary thyroid carcinoma and in patients with multiple endocrine neoplasia syndrome 2.
In patients with reanl failure, hepatic impairment and history of pancreatitis.
Nausea, vomiting, diarrhoea, weight gain, pancreatitis, bladder pain, low incidence of hypoglycaemia, formation of anti-liraglutide antibodies,acute tubular necrosis have been recently reported severe allergic reactions may occur.
Hormonal contraceptives, bosentan, barbiturates, felbamate, griseofulvin, carbamazapine, phenytoin, rifampicin, topiramate.
